
Making the ‘impossible’ executable in life sciences construction
Why early technical expertise matters when complex life sciences projects challenge convention.
Biotechnology: gene and cell therapies, gene editing, mRNA, biologics and new drugs, clinical trials and FDA decisions, and the biotech companies and investors behind them, from BioPharma Dive, STAT, GEN and the news, with research from Nature Biotechnology and journals.

Why early technical expertise matters when complex life sciences projects challenge convention.

The move from Phase II to Phase III is often treated as a clinical milestone, when it is actually a development-wide transition.

Cuba and China signed three biotechnology agreements in Shanghai on 6 November, a day after the US sanctioned two Chinese firms over military supplies to Cuba.

Once again, a hot new technology that was supposed to speed up drug research has fallen flat.

The model is a test of Trump's most-favored nation approach to drug pricing, though its impact is likely to be limited.

Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

“These results, the fact that they're negative, does not invalidate that inflammation plays a very important role in cardiovascular disease."

New cases show AAV gene therapies like Zolgensma carry tumor risks, raising key concerns for SMA patients and gene therapy researchers in general.
Pithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy…

5 Mins ReadA major survey by French dairy giant Danone has revealed that health is the biggest driver of plant-based dairy consumption globally, with gut digestion a chief factor, spelling out an opportunity for fibre-enriched, GLP-1-friendly alternatives. The taste of oat milk matters less than how it feels to your gut, according to a new study by

Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.

Three years ago, a trial for a sickle cell gene-editing therapy a decade in the making ended abruptly after the first patient suffered a serious adverse event. Now, the therapy…

A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."

Despite widespread opposition, Medicare will finalize a controversial proposal that will prevent providers, such as hospitals, from using third parties to deliver remote patient monitoring services.

Rasonque, Revolution Medicines' new pancreatic cancer drug, is off to one of the best oncology drug launches in history.

Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.

Following patient deaths, China restricts investigator-initiated biotech trials, leaving rare disease families and US investors facing an uncertain future.

Sanders could use his role in crafting the FDA funding bill to push for reforms.

Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.
It plans to back up to 12 biotech companies globally.
An AI agent performed brain surgery on an epileptic mouse, picking the drug, the brain target, and the injection coordinates on its own. According to lead researcher Ocana-Santero, it's the first time an AI agent has autonomously chosen a treatment and delivered it to a living mammal. But when a calibration error hit mid-surgery, the agent refused to continue and couldn't be talked out of it. The article A Claude model autonomously chose a gene therapy and operated on a…
GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that…
Beijing has vowed to defend its firms after Washington blocked imports from China’s leading genomics group, extending the two countries’ trade war into biotechnology weeks before their leaders are due to meet in Shenzhen. The US Department of Homeland Security (DHS) on Wednesday added three Shenzhen-based companies to the Uyghur Forced Labor Prevention Act (UFLPA)

6 Mins ReadGerman cocoa-free chocolate maker Planet A Foods has launched a single-ingredient Cocoa Booster powder to tackle rising costs and appeal to GLP-1 users via its high-fibre content. Planet A Foods, one of the leading startups in the alternative chocolate space, has its eye on the GLP-1 market with the rollout of Cocoa Booster, a one-ingredient
The iPROOF site in Decatur, IL, opens next May, and feature fermenters ranging from 1,200 to 10,000 liters alongside flexible DSP equipment.
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Are we there yet? A reality check on six big tech promises Some seemingly impossible feats are too good to give up on. Decoding a pet’s yowls and yips? Absolutely. Scrubbing…
Earlier this week, I attended a screening of You Can See Everything, the buzzy new documentary about the disgraced former biotech CEO Elizabeth Holmes. I went in not really knowing what to expect. I’d avoided spoilers (and won’t be giving anything away here, either!). I was wondering what new information this film could reveal, given…

4 Mins ReadUS supplements giant Herbalife and the Indian Institute of Technology Madras have established a Phyto Innovation accelerator programme to translate plant biotechnology research into scalable solutions. Months after opening a plant cell fermentation centre, US dietary supplements corporation Herbalife and the Indian Institute of Technology (IIT) Madras are building on their collaboration with a new biotech